Intel and MJFF Partner to Use Smartwatches in Parkinson’s Disease Study

Large datasets of information about patient symptoms, disease progression and drug effects can be a goldmine for understanding complex diseases. Aiming to better understand Parkinson’s disease (PD) and its clinical progression, Intel and the Michael J. Fox Foundation (MJFF) have partnered to collect such data from thousands of PD patients via smartwatches. In order to make sense of all the data, Intel has developed analytics platforms to collect, store and manage the data. This is not the first ‘big data’ initiative from the MJFF – in 2010, they created the Parkinson’s Progression Markers Initiative (PPMI), an observational clinical study to generate a comprehensive clinical database and biorepository for PD. These types of initiatives are also sprouting up in the ALS space and are facilitating new insights into the disease (see for example, the PRO-ACT database).

Large datasets of information about patient symptoms, disease progression and drug effects can be a goldmine for understanding complex diseases. Aiming to better understand Parkinson’s disease (PD) and its clinical progression, Intel and the Michael J. Fox Foundation (MJFF) have partnered to collect such data from thousands of PD patients via smartwatches. In order to make sense of all the data, Intel has developed analytics platforms to collect, store and manage the data. This is not the first ‘big data’ initiative from the MJFF – in 2010, they created the Parkinson’s Progression Markers Initiative (PPMI), an observational clinical study to generate a comprehensive clinical database and biorepository for PD. These types of initiatives are also sprouting up in the ALS space and are facilitating new insights into the disease (see for example, the PRO-ACT database).

Click here to read more.

Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail